Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | ACHE | P22303 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893609 | 0.79 | SIGMAR1 (0.55) | CCR3SIGMAR1ACHEHTR2ADRD2 | |
| SCHEMBL18574648 | 0.76 | SIGMAR1 (0.61) | SIGMAR1ALDH1A1DRD4MC4R | |
| SCHEMBL895077 | 0.76 | SIGMAR1 (0.61) | CCR3SIGMAR1ACHEALDH1A1DRD4 | |
| SCHEMBL894392 | 0.75 | SIGMAR1 (0.59) | CCR3SIGMAR1ACHEALDH1A1DRD4 | |
| SCHEMBL15140944 | 0.74 | CCR3 (0.73) | CCR3SIGMAR1ACHEALDH1A1CXCR4 | |
| SCHEMBL4257757 | 0.73 | ACHE (0.69) | CCR3SIGMAR1ACHEALDH1A1CXCR4 | |
| SCHEMBL8191786 | 0.73 | CCR3 (0.96) | CCR3SIGMAR1ACHEALDH1A1CXCR4 | |
| SCHEMBL7977320 | 0.73 | CCR3 (0.96) | CCR3SIGMAR1ACHEALDH1A1CXCR4 | |
| SCHEMBL2507062 | 0.72 | SIGMAR1 (0.55) | SIGMAR1ACHEALDH1A1DRD4MC4R | |
| SCHEMBL8188324 | 0.72 | SIGMAR1 (1.00) | CCR3SIGMAR1ACHEDRD4MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108547-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120101065-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120083470-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-8067395-B2 | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100035841-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7625880-B2 | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080039426-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108547-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | CCR3 2966/4885SIGMAR1 4271/4885ACHE 3396/4885 |
| US-20100035841-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | CCR3 2966/4885SIGMAR1 4271/4885ACHE 3396/4885 |
| US-20120083470-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | CCR3 2966/4885SIGMAR1 4271/4885ACHE 3396/4885 |
| US-20080039426-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | CCR3 2966/4885SIGMAR1 4271/4885ACHE 3396/4885 |
| US-20120101065-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | CCR3 2966/4885SIGMAR1 4271/4885ACHE 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.